Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression

Nat Metab. 2023 Jul;5(7):1159-1173. doi: 10.1038/s42255-023-00818-7. Epub 2023 Jun 19.

Abstract

Increased expression of branched-chain amino acid transaminase 1 or 2 (BCAT1 and BCAT2) has been associated with aggressive phenotypes of different cancers. Here we identify a gain of function of BCAT1 glutamic acid to alanine mutation at codon 61 (BCAT1E61A) enriched around 2.8% in clinical gastric cancer samples. We found that BCAT1E61A confers higher enzymatic activity to boost branched-chain amino acid (BCAA) catabolism, accelerate cell growth and motility and contribute to tumor development. BCAT1 directly interacts with RhoC, leading to elevation of RhoC activity. Notably, the BCAA-derived metabolite, branched-chain α-keto acid directly binds to the small GTPase protein RhoC and promotes its activity. BCAT1 knockout-suppressed cell motility could be rescued by expressing BCAT1E61A or adding branched-chain α-keto acid. We also identified that candesartan acts as an inhibitor of BCAT1E61A, thus repressing RhoC activity and cancer cell motility in vitro and preventing peritoneal metastasis in vivo. Our study reveals a link between BCAA metabolism and cell motility and proliferation through regulating RhoC activation, with potential therapeutic implications for cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acids, Branched-Chain / metabolism
  • Cell Proliferation
  • Humans
  • Keto Acids / metabolism
  • Neoplasms*
  • Proteins
  • Transaminases / metabolism

Substances

  • Proteins
  • Keto Acids
  • Amino Acids, Branched-Chain
  • Transaminases
  • BCAT1 protein, human